Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105926 | 0.91 | MCHR1 (0.68) | MCHR1KCNH2HRH3 | |
| SCHEMBL14639111 | 0.87 | MCHR1 (0.59) | MCHR1KCNH2HRH3 | |
| SCHEMBL7896380 | 0.85 | MCHR1 (0.59) | MCHR1KCNH2HRH3 | |
| SCHEMBL10080084 | 0.84 | MCHR1 (0.58) | MCHR1KCNH2HRH3 | |
| SCHEMBL112220 | 0.80 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL545100 | 0.79 | MCHR1 (0.50) | MCHR1KCNH2HRH3 | |
| SCHEMBL113480 | 0.78 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL166540 | 0.78 | MCHR1 (0.87) | MCHR1KCNH2HRH3 | |
| SCHEMBL14652386 | 0.77 | MCHR1 (0.61) | MCHR1KCNH2HRH3 | |
| SCHEMBL167857 | 0.77 | MCHR1 (0.85) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2424870-A1 | THERAPEUTIC AGENTS 713 | AstraZeneca AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | MC1R, MC2R, MC3R | MCHR1 4/4885KCNH2 4562/4885HRH3 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.